Abstract
Helicobacter pylori eradication is recognized as the initial therapy for gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma. This study assesses (i) the H. pylori eradication rates for various first- and second-line and rescue therapies and (ii) the associated reinfection rates in patients.
Lingua originale | English |
---|---|
pagine (da-a) | 1932-1932-7; quiz 1938 |
Rivista | THE AMERICAN JOURNAL OF GASTROENTEROLOGY |
Volume | 104 |
DOI | |
Stato di pubblicazione | Pubblicato - 2009 |
Pubblicato esternamente | Sì |
Keywords
- Drug Therapy, Combination
- Helicobacter Infections
- Helicobacter pylori
- Humans
- Lymphoma, B-Cell, Marginal Zone
- Recurrence
- Statistics as Topic
- Stomach Neoplasms